Dermira Inc (NASDAQ:DERM)’s share price traded up 5.1% during mid-day trading on Friday . The company traded as high as $8.55 and last traded at $8.51, 366,851 shares changed hands during trading. A decline of 72% from the average session volume of 1,327,665 shares. The stock had previously closed at $8.10.
A number of research analysts have recently issued reports on the stock. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research note on Wednesday, May 8th. Cantor Fitzgerald reiterated a “hold” rating and set a $8.00 price target on shares of Pacific Biosciences of California in a research note on Friday, May 3rd. Zacks Investment Research lowered shares of Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, July 16th. Finally, Mizuho assumed coverage on shares of Sabre in a research note on Thursday, June 6th. They set a “buy” rating and a $25.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. Dermira currently has a consensus rating of “Buy” and a consensus target price of $17.97.
The company has a market capitalization of $448.13 million, a PE ratio of -1.62 and a beta of 1.34. The business has a fifty day moving average price of $9.18. The company has a debt-to-equity ratio of 4.36, a quick ratio of 6.92 and a current ratio of 7.13.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.39). The company had revenue of $2.45 million for the quarter, compared to analysts’ expectations of $2.63 million. Dermira had a negative return on equity of 391.86% and a negative net margin of 510.47%. On average, equities analysts expect that Dermira Inc will post -5.2 EPS for the current fiscal year.
Hedge funds have recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Dermira by 356.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 12,912 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 10,085 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Dermira in the fourth quarter valued at about $95,000. BNP Paribas Arbitrage SA lifted its holdings in shares of Dermira by 48,273.3% in the first quarter. BNP Paribas Arbitrage SA now owns 7,256 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 7,241 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in shares of Dermira in the second quarter valued at about $120,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Dermira by 2,500.0% in the first quarter. Nisa Investment Advisors LLC now owns 10,400 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 10,000 shares in the last quarter. 93.92% of the stock is currently owned by hedge funds and other institutional investors.
Dermira Company Profile (NASDAQ:DERM)
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Further Reading: What are municipal bonds?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.